Finance

Lists
Outlook: 45.5% bullish·0.0% bearish
Go to analysis
LH:NYSE
Labcorp Holdings Inc
$321.02
+0.69%
(+2.19) 1D
Oct 20, 2:59:19 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LH...
Open
$321.10
High
$324.50
Low
$317.96
Mkt. cap
26.03B
Avg. vol.
769.36K
Volume
269.72K
Dividend
0.90%
Quarterly dividend
$0.72
Ex-dividend date
May 29, 2026
P/E ratio
26.55
52-wk high
$341.80
52-wk low
$244.52
EPS
$12.09
Beta
0.88
Shares outstanding
81.10M
No. of employees
71K
Open
$321.10
High
$324.50
Low
$317.96
Mkt. cap
26.03B
Avg. vol.
769.36K
Volume
269.72K
Dividend
0.90%
Quarterly dividend
$0.72
Ex-dividend date
May 29, 2026
P/E ratio
26.55
52-wk high
$341.80
52-wk low
$244.52
EPS
$12.09
Beta
0.88
Shares outstanding
81.10M
No. of employees
71K
News stories
From web sources and news partners
Profile
Labcorp Holdings Inc., operating under the brand name Labcorp, headquartered in Burlington, North Carolina, provides laboratory services used for diagnosis and healthcare decisions. It operates one of the largest clinical laboratory networks in the world and has operations in over 100 countries; although its operations are primarily in the U.S. Its Diagnostics Laboratories segment operates 2,000 patient service centers with more than 6,000 in-office phlebotomists in the United States. In addition to healthcare testing such as oncology testing, human immunodeficiency virus genotyping and phenotyping, it provides testing for: employment, DNA testing to determine parentage and to determine immigration eligibility, environmental issues, wellness, toxicology, pain management, and medical drug monitoring. It also provides 50 tests that patients can complete at home. It processes over 160 million tests per year. Approximately 10% of this segment’s revenue are from the U.S. Medicare health insurance program. Wikipedia
About Labcorp Holdings Inc
CEOAdam H. Schechter
Employees71K
Founded1978
HeadquartersBurlington, North Carolina, United States
SectorHealth care provider
Websitelabcorp.com
Analyst ratings
Based on 13 analysts giving stock ratings to LH in the past 3 months
Strong buy
Buy
10
Hold
3
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for LH in the last 3 months.
Highest
Current $321.02
$380.00 (+18.37%)
Average
$343.50 (+7.00%)
Lowest
$306.00 (-4.68%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kevin Caliendo
UBS
Buy
Maintained
$380.00
+18.4%
10/19/2026
Lu Li
Bank of America Securities
Buy
Maintained
$360.00
+12.1%
10/15/2026
Luke Sergott
Barclays
Hold
Maintained
$330.00
+2.8%
10/07/2026
Michael Cherny
Leerink Partners
Buy
Reiterated
-
-
09/23/2026
David S Macdonald
Truist Financial
Buy
Maintained
$365.00
+13.7%
09/21/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$340.00
+5.9%
09/11/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
09/11/2026
Lisa Gill
J.P. Morgan
Buy
Maintained
-
-
08/26/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
$355.00
+10.6%
08/10/2026
David Westenberg
Piper Sandler
Hold
Reiterated
$309.00
-3.7%
08/04/2026
Pito Chickering
Deutsche Bank
Hold
Reiterated
$306.00
-4.7%
07/31/2026
Erin Wright
Morgan Stanley
Buy
Maintained
$338.00
+5.3%
07/31/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
$352.00
+9.7%
07/31/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
$360.00
+12.1%
07/30/2026
David Toung
Argus Research
Buy
Maintained
$310.00
-3.4%
06/02/2026
Unknown Analyst
Mizuho Securities
Buy
Reiterated
$320.00
-0.3%
05/27/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
04/30/2026
Next call in 8 days
Wed, Oct 28, 3:00 PM
Fiscal period
Q3 2026
- / $4.65
Revenue / Est. (USD)
- / 3.76B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.56B
3.52B
3.54B
3.73B
Cost of goods sold
2.54B
2.52B
2.52B
2.62B
Cost of revenue
2.54B
2.52B
2.52B
2.62B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
552.40M
549.70M
551.00M
577.20M
Operating expense
621.90M
622.30M
626.60M
655.30M
Total operating expenses
3.16B
3.14B
3.15B
3.27B
Operating income
403.20M
370.90M
387.20M
456.70M
Other non operating income
700.00K
1.90M
-600.00K
-3.50M
EBT including unusual items
337.00M
190.60M
319.70M
386.40M
EBT excluding unusual items
341.30M
315.20M
333.20M
391.50M
Income tax expense
75.50M
25.70M
41.70M
87.30M
Effective tax rate
22.40%
13.48%
13.04%
22.59%
Other operating expenses
-
-
-
-
Net income
261.10M
164.70M
277.80M
298.70M
Net profit margin
7.33%
4.68%
7.85%
8.01%
Earnings per share
4.18
4.07
4.25
4.99
Interest and investment income
3.50M
3.50M
12.20M
5.60M
Interest expense
-56.00M
-55.00M
-55.10M
-61.10M
Net interest expenses
-52.50M
-51.50M
-42.90M
-55.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
574.20M
549.40M
560.50M
635.70M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps